Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6...
45 insider purchases on record · latest filing 2025-12-11.
Insiders have also filed 521 sale transactions at KYMR.